Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14356/1151
Title: | Lymphocyte Levels in Predicting the Outcome of COVID-19 Patient: A Prognostic Study from Single Center in Indonesia |
Authors: | Amin, Chris Alberto Liana, Phey Ahmad, Zen Hidayat, Rachmat Sari, Nurmalia Purnama Afifah, Astari Rahayu Hilda, Fadhilatul |
Citation: | AminC. A., LianaP., AhmadZ., HidayatR., SariN. P., AfifahA. R., & HildaF. (2021). Lymphocyte Levels in Predicting the Outcome of COVID-19 Patient: A Prognostic Study from Single Center in Indonesia. Journal of Nepal Health Research Council, 19(03), 536-542. https://doi.org/10.33314/jnhrc.v19i3.3529 |
Issue Date: | 2021 |
Publisher: | Nepal Health Research Council |
Article Type: | Original Article |
Keywords: | COVID-19 lymphopenia mortality prognosis survival analysis |
Series/Report no.: | July-Sep, 2021;3529 |
Abstract: | Abstract Background: Several laboratory parameters have been linked to Corona Virus Disease 2019 (COVID-19), with lymphocytes being one of the most important. Lymphopenia is frequently linked to a worsening of clinical symptoms and an increased risk of death in COVID-19. This study aimed to determine the role of lymphocyte levels in predicting COVID-19 patient mortality. Methods: This is a prognostic study that is conducted from March 1 to August 31, 2020. Data from medical records and laboratory findings of COVID-19 patients were used in the study. Patient distribution and complete blood count were among the information gathered. ROC curve analysis, bivariate analysis (Chi-Square and Mann Whitney), in addition to survival analysis (Kaplan-Meier) were used to analyze the data. Results: In a total of 318 patients, 59 were non-survivors and 259 were survivors. Besides, a cut-off value of ?1460 cells/µL (P<0.05) was used for lymphocyte levels. Lymphopenia also has a 4.35-fold increase in the risk of mortality. Furthermore, the survival analysis revealed differences in the probability of survival within 30 days between COVID-19 patients with lymphopenia and those without (HR: 5.5722 (3.2509–9.5510), 95% CI; p<0.0001). A lymphocyte count of ?1460 cell/µL can increase the risk of death by fourfold. Conclusions: The findings of this study indicated a significant difference in outcome between lymphopenia and non-lymphopenia patients. Lymphopenia plays an important role in estimating COVID-19 patient mortality. Keywords: COVID-19; lymphopenia; mortality; prognosis; survival analysis |
Description: | Original Article |
URI: | http://103.69.126.140:8080/handle/20.500.14356/1151 |
ISSN: | Print ISSN: 1727-5482; Online ISSN: 1999-6217 |
Appears in Collections: | Vol. 19 No. 03 (2021): Vol 19 No 3 Issue 52 Jul-Sep 2021 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
3529-Manuscript-25072-1-10-20211215.pdf | Fulltext Download | 391.58 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.